Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic instability and increased mutational load: which diagnostic tool best direct patients with cancer to immunotherapy?

Journal of translational medicine - 21 Jan 2017

Palmieri Giuseppe, Colombino Maria, Cossu Antonio, Marchetti Antonio, Botti Gerardo, Ascierto Paolo A

Abstract excerpt

The occurrence of high rates of somatic mutations in cancer is believed to correspond to increased frequency of neo-epitope formation and tumor immunogenicity. Thus, classification of patients with cancer according to degree a somatic hyper-mutational status could be proposed as a predictive biomarker of responsiveness to immunotherapy with immune checkpoint inhibitors. Here, we discuss the suitable and reliable...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immunotherapy
Share to DNA, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Electrophoresis, Agar Gel

Share to Genetic Loci

Share to Genomic Instability

Share to Microsatellite Repeats

Share to Mutation

Share to Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 28109293
DOI: 10.1186/s12967-017-1119-6
PMCID: PMC5251272

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic instability and increased mutational load: which diagnostic tool best direct patients with cancer to immunotherapy?PMID 28109293Read ↗

Tumor Mutational Burden as a Biomarker of Immunotherapy Response: An Immunogram Approach in Onco-immunology.Semantic proximity Read ↗

Hypermutation, Mismatch Repair Deficiency, and Defining Predictors of Response to Checkpoint Blockade.Semantic proximity Read ↗

Of Context, Quality, and Complexity: Fine-Combing Tumor Mutational Burden in Immunotherapy-Treated Cancers.Semantic proximity Read ↗

Tumour mutational burden: an overview for pathologists.Semantic proximity Read ↗

Hypermutated Tumors and Immune Checkpoint Inhibition.Semantic proximity Read ↗

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinicSemantic proximity Read ↗

Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.Semantic proximity Read ↗

The Spectrum of Benefit from Checkpoint Blockade in Hypermutated TumorsSemantic proximity Read ↗

The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker.Semantic proximity Read ↗

Hypermutation as a Potential Predictive Biomarker of Immunotherapy Efficacy in High-Grade Gliomas: A Broken Dream?Semantic proximity Read ↗

Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts.Semantic proximity Read ↗

Tumor mutational burden: why is it still a controversial agnostic immunotherapy biomarker?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.